Taivex announced that the latest clinical trial results of its novel anticancer drug candidate T-1101 have been accepted for poster presentation at the 2025 European
Taivex announced that its investigational drug T-1101 has received approval from Taiwan’s Food and Drug Administration (TFDA) to initiate Phase II clinical trials. The study
The 2025 ASCO Annual Meeting will be held from May 30 to June 3 in Chicago, USA. ASCO (American Society of Clinical Oncology) is the
Taivex announced that the latest clinical trial data for its novel anticancer drug candidate T-1101 has been accepted for online publication at the 2025 American
Taivex announced that T-1101 has received approval from the U.S. Food and Drug Administration (FDA) to advance to Phase II clinical trials. This trial will
Taivex announced that its Phase I clinical trial drugs, T-1101 and T-1201, have been invited to present their project progress at the Korean Society of
Taivex is dedicated to the development of novel cancer therapeutics and possesses multiple First-in-Class/Best-in-Class anticancer targeted drugs. Taivex will attend the Bio Asia-Taiwan 2024, BIO
The groundbreaking discovery and development of T-1201, a novel targeting small molecule-drug conjugate (SN38), and T-1301, an innovative multi-targeted tyrosine kinase inhibitor (TKI), have been
Taivex has announced that all three Phase I clinical projects, T-1101, T-1201, and T-1301, have been selected to present their project progress at the American
Taivex Therapeutics attended the 2024 BIO-Europe SPRING conference in Barcelona, Spain (https://informaconnect.com/bioeurope-spring/) from March 18th to 20th. During the conference, Taivex engaged in discussions with
